<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01082861</url>
  </required_header>
  <id_info>
    <org_study_id>LIS144</org_study_id>
    <secondary_id>2010-018459-86</secondary_id>
    <nct_id>NCT01082861</nct_id>
  </id_info>
  <brief_title>Efficacy and Immunomodulation Study of Simultaneous Human Papillomavirus/ Hepatitis B (HPV/HBV) Vaccination</brief_title>
  <acronym>TANGO</acronym>
  <official_title>A Phase 4, Randomized, Open Label Clinical Trial to Determine Efficacy and Immunomodulation of Simultaneous HPV/HBV Vaccination Tango-trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute for Public Health and the Environment (RIVM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute for Public Health and the Environment (RIVM)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:&#xD;
&#xD;
      In march 2009 the Dutch Health Council advised to introduce general infant hepatitis B (HBV)&#xD;
      vaccination in the Dutch national immunization program (NIP) {Gezondheidsraad 2009 #16914}.&#xD;
      To reach the anticipated health benefits earlier, a catch-up vaccination in pre-adolescents&#xD;
      should complement the program, for girls preferably combined with human papillomavirus (HPV)&#xD;
      vaccination at the age of 12 years. Although the rationale is clear, particular aspects of&#xD;
      combining HPV and HBV vaccination deserve further attention, especially as it has been shown&#xD;
      that combining HPV and HBV vaccination results in reduced HBV immunogenicity/seroresponses&#xD;
      {Wheeler, Bautista, et al. 2008 #17284}{Pedersen 2009 #16684}. The reason for this&#xD;
      interference is unknown, but might be due to concomitant use of different antigens and/or&#xD;
      adjuvants, possibly skewing immunity in opposite directions. Despite proven immunostimulatory&#xD;
      effects, the use of (new) adjuvants has raised safety concern among the general public as&#xD;
      well {Israeli, Agmon-Levin, et al. 2009 #16924}.&#xD;
&#xD;
      Objective, Study design and Study population:&#xD;
&#xD;
      In view of the observations and concerns mentioned above, further investigation into&#xD;
      interference of HPV and HBV vaccination and adjuvant use is justified. In this context RIVM&#xD;
      propose to study single vs simultaneous HBV and HPV vaccination in 11-12-year-old girls while&#xD;
      monitoring antigen-related and antigen-unrelated immunological parameters. The anticipated&#xD;
      results will elucidate the extent of interference between simultaneous HPV and HBV&#xD;
      vaccination in the target group, and guide the choice for a HBV vaccine and schedule when the&#xD;
      HBV catch-up program is indeed introduced. Furthermore, specific immunological trends post&#xD;
      single and combined HPV and HBV vaccination will be elucidated, increasing the investigators&#xD;
      comprehension of adjuvant use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to recent strategic policy developments in the national vaccination program it is uncertain&#xD;
    preadolescent girls will receive the HBV vaccin.&#xD;
  </why_stopped>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">April 2011</completion_date>
  <primary_completion_date type="Anticipated">April 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Antibody seroprotection proportion for HBV in groups 1, 2 and 3 measured in Sample 2.</measure>
    <time_frame>Month 7</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Human Papillomavirus Infection</condition>
  <arm_group>
    <arm_group_label>HPV&amp;HBV vaccin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV&amp;HBV vaccin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HPV vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HPV vaccination</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HBV vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HBV vaccination</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix</intervention_name>
    <description>Cervarix, HPV vaccin</description>
    <arm_group_label>HPV vaccination</arm_group_label>
    <arm_group_label>HPV&amp;HBV vaccin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Engerix-B</intervention_name>
    <description>Engerix-B, HBV vaccin</description>
    <arm_group_label>HBV vaccination</arm_group_label>
    <arm_group_label>HPV&amp;HBV vaccin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female pre-adolescents born in 1998, eligible for HPV vaccination in 2011.&#xD;
&#xD;
          2. Able to fulfill all study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous vaccination with any licensed or experimental HPV or HBV vaccine.&#xD;
&#xD;
          2. Contraindication for vaccination with Cervarix®.&#xD;
&#xD;
          3. Contraindication for vaccination with Engerix-B®.&#xD;
&#xD;
          4. Use of investigational vaccine or medication within 30 days before study&#xD;
&#xD;
          5. History of severe adverse reaction associated with a vaccine or vaccine component.&#xD;
&#xD;
          6. Heart disease&#xD;
&#xD;
          7. Liver disease&#xD;
&#xD;
          8. Spleen removal&#xD;
&#xD;
          9. Asthma&#xD;
&#xD;
         10. Immune deficiency or suppression&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>11 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>March 8, 2010</study_first_submitted>
  <study_first_submitted_qc>March 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 9, 2010</study_first_posted>
  <last_update_submitted>March 18, 2010</last_update_submitted>
  <last_update_submitted_qc>March 18, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2010</last_update_posted>
  <responsible_party>
    <name_title>Hein Boot, section head LIS</name_title>
    <organization>Institute of Public Health and the Environment</organization>
  </responsible_party>
  <keyword>1998 female birth cohort eligible for HPV vaccination in 2011 within the Dutch NIP</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

